Johnson & Johnson (JNJ) Projected to Post Earnings on Tuesday

Johnson & Johnson (NYSE:JNJ - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, April 15th. Analysts expect the company to announce earnings of $2.59 per share and revenue of $21.65 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.500-10.700 EPS and its FY25 guidance at $10.50-10.70 EPS.Investors that are interested in registering for the company's conference call can do so using this link.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.29 earnings per share. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Stock Up 2.0 %

JNJ stock traded up $2.93 during trading hours on Friday, hitting $151.62. The company's stock had a trading volume of 9,940,249 shares, compared to its average volume of 7,949,830. The company has a market capitalization of $365.39 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The stock has a 50 day moving average price of $159.40 and a two-hundred day moving average price of $155.21. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Remove Ads

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Institutional Trading of Johnson & Johnson

An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 51,876 shares of the company's stock after purchasing an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 as of its most recent filing with the SEC. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Bank of America reduced their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Finally, Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $171.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.